Evotec SE Stock
€14.15
Your prediction
Evotec SE Stock
Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Pros and Cons of Evotec SE in the next few years
Pros
Cons
Performance of Evotec SE vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Evotec SE | 3.280% | 0.000% | 1.406% | -23.055% | -35.861% | -59.670% | -37.557% |
| MorphoSys AG | -0.070% | -0.147% | 1.119% | 256.861% | 98.680% | -11.944% | -21.676% |
| Novocure Ltd | 2.030% | -5.219% | -6.738% | -80.123% | -20.490% | -93.150% | - |
| Iovance Biotherapeutics Inc. | 3.430% | -4.917% | -23.544% | 99.307% | 36.206% | -58.970% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, the financial statements of Evotec, a prominent company within the Biotechnology and Medical Research industry, exhibit a combination of both favorable and concerning aspects. As a financial analyst, it is essential to delve into these documents to understand the company's financial health and potential opportunities for growth.
*Pros: *
Growing Total Assets: The total assets of Evotec have consistently grown over the last three years, increasing from €1,180,912,000 in 2019 to €1,462,895,000 in 2020, and further to €2,235,161,000 by the end of 2021. This growth reflects the company's ability to expand and generate value over time.
Comments
News
EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer